Theseus goes with Tang; Oncternal trial patient dies; LianBio sells drug rights to J&J
Plus, news on the Immunome-Atreca asset deal, Cyclo Therapeutics’ reverse merger, Nestlé buying CDX-7108 from Codexis, Oncternal, Visiox and more.
So long, Applied Molecular Transport: The stock symbol $AMTI officially became history as Cyclo Therapeutics completed its reverse merger and took Applied Molecular Transport’s spot on the Nasdaq under the ticker $CYTH. Applied Molecular Transport began hunting for strategic alternatives in late March after it halted all R&D activities and laid off the bulk of its staff in the wake of a Phase II flop in ulcerative colitis. The deal with Cyclo was announced in September. The company will now focus on a Phase III study of its reformulated drug for Niemann-Pick Disease Type C1. — Amber Tong
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.